EPA085 Vitamin D supplementation enhances cytotoxic response in patients with severe COVID-19E-posterImmune responses to SARS-Cov2
EPA087 Limited immunogenicity of SARS-CoV-2 vaccine in people living with HIV (PWH) and low nadir CD4 countsE-posterSARS-Cov2 vaccines
EPA088 Adverse events following COVID-19 vaccination among people with HIV: review of available vaccine safety literatureE-posterSARS-Cov2 vaccines
EPA089 Potent cytotoxic activity against SARS-CoV-2 of CD8+ T cells from individuals with HIV who received complete schedule of COVID-19 vaccinesE-posterSARS-Cov2 vaccines
EPA090 Factors associated with SARS-CoV2 vaccination acceptance in people with HIV participating in the SCAPE-HIV studyE-posterSARS-Cov2 vaccines
EPA091 Immunogenicity of mRNA-1273 COVID-19 vaccination in PLWH after inadequate primary vaccination responseE-posterSARS-Cov2 vaccines
EPA092 SARS-CoV-2 Omicron Spike recognition by plasma fromindividuals receiving BNT162b2 mRNA vaccination with a 16-weeks interval between dosesE-posterSARS-Cov2 vaccines
EPA093 Detection of pre-existing neutralizing antibodies against Ad26 in HIV-1-infected Individuals not responding to the Ad26.COV2.S vaccineE-posterSARS-Cov2 vaccines
EPA094 Characterization of serum and mucosal SARS-CoV-2-antibodies in HIV-1 infected subjects after BNT162b2 mRNA vaccination or SARS-CoV-2 infectionE-posterSARS-Cov2 vaccines
EPB001 Factors influencing immune restoration in people living with HIV/AIDSE-posterImpact of co-factors (e.g., viral clade, tropism, genetic factors) on disease progression
81 - 90 of 2485 items